Published in Curr Alzheimer Res on September 30, 2016
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 11.49
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
Tumor necrosis factor signaling. Cell Death Differ (2003) 8.48
The molecular pathology of Alzheimer's disease. Neuron (1991) 8.21
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A (1997) 6.99
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci (1991) 5.71
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A (1997) 5.66
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
TNF-mediated inflammatory disease. J Pathol (2008) 5.00
Reflex control of immunity. Nat Rev Immunol (2009) 4.57
The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol (2009) 4.53
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Classification and basic pathology of Alzheimer disease. Acta Neuropathol (2009) 3.24
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Inflammatory processes in Alzheimer's disease. J Neuroimmunol (2007) 2.91
A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1992) 2.79
IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab (2003) 2.59
Role of myokines in exercise and metabolism. J Appl Physiol (1985) (2007) 2.52
Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol (1999) 2.46
Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J (2003) 2.31
Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev (2008) 2.30
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology (2015) 2.27
Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol (1999) 2.26
Protective effects of NSAIDs on the development of Alzheimer disease. Neurology (2008) 2.21
Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci (2005) 2.18
How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol (2006) 2.14
A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry (2010) 2.06
A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal (2012) 2.03
Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation (1996) 1.94
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem (2004) 1.88
The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol (2010) 1.75
The role of cytokines in sleep regulation. Curr Pharm Des (2008) 1.73
Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2001) 1.70
Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun (2008) 1.70
Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc (2013) 1.69
Signaling via NF-kappaB in the nervous system. Biochim Biophys Acta (2005) 1.63
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest (2006) 1.58
TNF ligands and receptors--a matter of life and death. Br J Pharmacol (2002) 1.57
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed (2006) 1.56
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
TNFα controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron (2011) 1.54
Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol (2007) 1.54
Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol (2007) 1.53
TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J (1999) 1.48
'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci (2010) 1.47
Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology (2007) 1.45
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation (2008) 1.45
Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol (2005) 1.41
Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia (2006) 1.41
Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol (2011) 1.39
TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res (2007) 1.38
Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis (1999) 1.38
Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm (2014) 1.35
Neurologic complications of FK 506. Transplant Proc (1991) 1.34
Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal (2010) 1.34
γ-Secretase inhibitors and modulators. Biochim Biophys Acta (2013) 1.32
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 1.30
The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation (2011) 1.26
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev (2012) 1.26
NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol (2006) 1.26
Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.25
TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol (2002) 1.24
Neurotoxicity of immunosuppressive drugs. Liver Transpl (2001) 1.24
Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care (2007) 1.23
Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care (2003) 1.23
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol (2013) 1.23
Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol (2006) 1.22
The case for rejecting the amyloid cascade hypothesis. Nat Neurosci (2015) 1.21
Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci (2013) 1.21
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation (2003) 1.18
Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport (1998) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport (2001) 1.17
Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler (2011) 1.16
Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging (2001) 1.15
Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro. J Neurosci Res (2005) 1.15
High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis (2006) 1.13
Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev (2015) 1.13
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation (2012) 1.13
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull (2003) 1.10
Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun (2009) 1.10
Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci (2012) 1.09
Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev (2013) 1.09
Immunomodulatory drugs. Cancer Invest (2005) 1.09